CD86 and neoplasm: We also observed a higher number of cDC1s in the lung-draining mediastinal lymph nodes (mLN) (Fig. 4d) and an enhanced surface expression of CD86, CD40, and XCR1 (Fig. 4e), suggesting that BCG treatment induced the migration of activated cDC1s from the tumor site to the mLN, where they are expected to initiate adaptive immune responses.